Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(8):636-637; doi:10.1093/jnci/djh108
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Decaudin, D.
Right arrow Articles by Pouillart, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Decaudin, D.
Right arrow Articles by Pouillart, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

CORRESPONDENCE

Multicenter Phase II Feasibility Trial of High-Dose Tamoxifen in Patients With Refractory or Relapsed Multiple Myeloma

Didier Decaudin, Marie-Christine Etienne, Patricia de Cremoux, Zofia Maciorowski, Jean-Marie Vantelon, Eric Voog, SaÏk Urien, Carine Tran-Perennou, Nicole Renée, Philippe Vielh, Fariba Némati, Pierre Pouillart

Affiliations of authors: Department of Clinical Hematology (DD, FN), Department of Tumor Biology (PDC, ZM, CTP, PV), Department of Medical Oncology (PP), Institut Curie, Paris, France; Department of Oncopharmacology, Centre Antoine Lacassagne, Nice, France (MCE, NR); Department of Clinical Hematology, Institut Gustave Roussy, Villejuif, France (JMV); Department of Clinical Hematology, Centre Jean Bernard, Le Mans, France (EV); Department of Pharmacology, Centre René Huguenin, Saint-Cloud, France (SU)

Correspondence to: Didier Decaudin, MD, PhD, Service d’Hématologie Clinique, Institut Curie, 26 rue d’Ulm, 75.248 Paris CEDEX 05, France (e-mail: didier.decaudin@curie.net)

The first 10% of the full text of this article appears below.

Despite high-dose chemotherapy with autologous stem cell transplantation, most patients with multiple myeloma relapse and eventually die. Previous studies have suggested that multiple myeloma cells express estrogen receptors and that antiestrogens induce in vitro growth inhibition and apoptosis of tumor cells (1–3). We therefore conducted a phase II feasibility trial of high-dose tamoxifen in patients with relapsed or . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?